Developer docs
API playgroundTry for free, no card

Search company profiles

React4life

Full company profile

uuid0003qr9

Namestring
React4life
Legal namestring
React4Life
Websiteurl
react4life.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

React4Life Srl is a privately held Italian biotech company founded in 2017 by Dr. Silvia Scaglione, headquartered in Genoa. It develops and commercializes the MIVO® (Millifluidic Vessel Organ) organ-on-chip platform, a patented technology that combines clinically relevant 3D tissue size with independently controlled millifluidic flow environments for in vitro drug discovery, toxicity testing, and translational research. The platform includes MIVO® Single Flow and Double Flow chamber kits, the 3D-flowGel ready-to-use hydrogel, and the TOKYO high-throughput fluidic module with 24 parallel lines, supporting applications in cancer and immunology, gut/nutraceuticals, dermocosmetics and medical devices, and biotech/pharmaceutical development. A multi-organ Cancer-Liver-on-Chip configuration and integrated custom assay services extend the platform toward combination efficacy and hepatoxicity studies.

React4Life monetizes through a mix of hardware sales (MIVO® chamber kits, 3D-flowGel, TOKYO module), custom cell-based assay services, and research-use licensing, with pricing handled via quote requests rather than public list prices. The go-to-market combines direct enterprise field sales with marketplace distribution through Scientist.com and Skinobs, supplemented by a heavy content and event presence — webinars, workshops, publications, and industry conference participation — targeting pharma, biotech, dermocosmetics, nutraceutical, and academic customers. Reported performance metrics include 92–95% concordance with clinical drug responses using patient-derived samples and reproducible results with sub-2% standard deviations in dermal absorption assays.

The company is founder-led, with Dr. Scaglione as Chief Scientist and Maurizio Aiello as CEO, holds 7 patents tied to the founder and the company, and has earned recognition including the 2023 CPHI Award, the EU Innovation Radar Award for Best Health Technology, the 2021 Gamma Donna Innovative Start-up Award, and a 2024 European Innovation Council Ambassador nomination. In February 2026 it became a founding member of IAMPS, the European industry association for microphysiological systems providers. Revenue and headcount figures are not publicly disclosed; team size is reported at 1–10 employees.

Short descriptiontext

React4Life Srl is a Genoa-based biotech company developing the MIVO® millifluidic organ-on-chip platform and 3D-flowGel hydrogel for predictive 3D in vitro drug testing. It serves pharmaceutical, biotech, dermocosmetics, nutraceutical, and academic customers via direct sales, custom assay services, and marketplace partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGenova, Italy
HQ citystring
Genova
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organ-on-chip technology, in vitro tissue models, drug discovery platforms, 3D cell culture, preclinical testing services
Industry1 code
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Surgical & Medical Instruments & Apparatus3841
Product category
Organ-on-Chip Technology
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1MIVO® Hardware Sales
TypeHardware Sales
Description

Sale of MIVO® organ-on-chip devices including Single Flow Box (12 MIVO® chambers, 12 single flow lids) and Double Flow Box (12 MIVO® chambers, 12 double flow lids). Devices are sterile and individually blistered for quick and easy use.

react4life.com
2Cell-based Assay Services
TypeProfessional Services
Description

Expert R&D team collaborates with customers to design and develop tailored assays. Testing services provide more predictive results with high accuracy and reliability, delivering fast and precise data.

react4life.com
33D-flowGel Sales
TypeHardware Sales
Description

Sale of 3D-flowGel 3D cell culture matrix product for in vitro cell culture applications.

react4life.com
4Technology Licensing
TypeLicensing Royalties
Description

The company offers technology licensing through terms and conditions for 'Supply of Products and Services – Research Use', indicating licensing arrangements for their proprietary technology.

react4life.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Custom quote-based pricing for MIVO® products and services
ModelOtherBilling cadenceMulti-year contract
Notes

No publicly listed pricing available. Customer inquiries handled through GET A QUOTE form on website. Workshop fees include training cost, brochures, MIVO device and all reagents required for experiments.

react4life.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1MIVO®
Description

Proprietary organ-on-chip technology platform combining clinically relevant tissue size with independent millifluidic environments for drug discovery and toxicity testing.

react4life.com
+2 more records
Core offering1 text field

React4life develops and manufactures the patented MIVO® (Millifluidic Vessel Organ) organ-on-chip platform, a hardware system that combines clinically relevant 3D tissue models with independently controlled millifluidic flow environments for drug discovery and translational research. The company sells MIVO Single Flow and Double Flow device boxes, the 3D-flowGel hydrogel consumable, and the high-throughput TOKYO fluidic module, and complements these with custom cell-based assay development services for biotech, pharmaceutical, dermocosmetics, and nutraceutical clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 92-95% concordance with clinical drug responses vs. conventional 2D cultures
+4 more records
Product overview1 text field

React4Life offers a platform-based product ecosystem centered on the MIVO® millifluidic organ-on-chip technology. The core MIVO® platform is available in Single Flow and Double Flow configurations, combined with 3D-flowGel hydrogel for 3D cell culture. The platform serves four application divisions: Cancer & Immunology (Cancer-on-Chip), Nutraceuticals Food & Feed (Gut-on-Chip), Dermocosmetics Medical Device (Skin-on-Chip), and Biotech Pharmaceutical. Supporting services include custom assay development and scientific support, with resources including publications, workshops, webinars, and application notes documenting research applications.

Product and service1 record
1MIVO Single Flow
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

React4Life is a founding member of IAMPS, the world's first industry association dedicated to representing microphysiological systems providers across Europe. The association aims to increase regulatory acceptance of MPS data, create data-sharing platforms, and advance device standardization. Expected to become operational in Q2 2026.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Fellow founding member of IAMPS industry alliance, headquartered in Switzerland. Collaborates with React4Life on regulatory acceptance and standardization of MPS technologies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Fellow founding member of IAMPS industry alliance from Italy. Part of the nine founding members working to advance microphysiological systems in Europe.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Fellow founding member of IAMPS industry alliance from Italy. Contributing to regulatory acceptance and standardization efforts.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Fellow founding member of IAMPS industry alliance from Germany. Part of the nine founding companies advancing MPS technologies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Fellow founding member of IAMPS industry alliance from Switzerland. Contributing to data-sharing platforms and device standardization.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Fellow founding member of IAMPS industry alliance from the Netherlands. Partnered with React4Life on regulatory acceptance and MPS data standards.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Fellow founding member of IAMPS industry alliance from France. Part of the nine founding members advancing organ-on-chip technologies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Fellow founding member of IAMPS industry alliance from Germany. Partnered with React4Life in this industry association for microphysiological systems.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint webinar collaboration with PromoCell on advancing reproducible 3D cancer models into dynamic cancer-on-chip systems. PromoCell provides cancer media toolbox supporting CSC-driven growth across multiple cancer types.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic collaboration between React4Life and Prodeco Pharma to evaluate protective and reparative effects of GSE Reflusolve Rapid using MIVO® esophagus-on-chip platform in GERD research.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swiss lung-on-chip company with alveolar and airway models for respiratory drug testing. Direct peer in MPS and IAMPS co-founding member serving pharma and inhaled therapeutics customers.

TypeDirect peer
Description

Dutch organ-on-chip company developing the OrganoPlate platform for high-throughput 3D tissue models. Direct peer offering competing organ-on-chip products to pharma R&D, and co-founding member of IAMPS with React4Life.

TypeDirect peer
Description

Swiss 3D cell culture and organ-on-chip company serving pharma toxicology and disease modeling. Direct peer in microphysiological systems and fellow IAMPS founding member, targeting the same biotech and pharma customers.

TypeDirect peer
Description

German multi-organ-on-chip company with a HUMIMIC platform for connected organ models. Direct peer in MPS/multi-organ-chip, and fellow IAMPS founding member addressing the same pharma and cosmetics testing customers.

TypeDirect peer
Description

US-based organ-on-chip company and one of the most capitalized players in the space, with the Emulate platform serving pharma R&D. Direct peer with deeper commercial scale and broader enterprise penetration.

6CN Bio
TypeDirect peer
Description

UK organ-on-chip company offering the PhysioMimix platform for drug discovery and toxicology. Direct peer targeting the same pharma ADME/Tox and disease modeling applications as React4Life.

TypeDirect peer
Description

German organ-on-chip company developing immune and infection models using microfluidic chip technology. Direct peer and IAMPS founding member addressing pharma and academic customers.

TypeDirect peer
Description

French organ-on-chip company specializing in neuro-on-chip and microfluidic devices for pharma and cosmetics. Direct peer and IAMPS founding member targeting adjacent applications to React4Life's platform.

TypeDirect peer
Description

Italian organ-on-chip company developing multi-organ and disease models. Direct peer in MPS, fellow Italian company, and IAMPS founding member competing for similar European pharma and academic customers.

TypeDirect peer
Description

US organ-on-chip company providing microfluidic tissue models for drug development and toxicity testing. Direct peer offering competing OoC hardware and services to pharma researchers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

React4life

Organ-on-Chip Technologyreact4life.com

React4Life Srl is a Genoa-based biotech company developing the MIVO® millifluidic organ-on-chip platform and 3D-flowGel hydrogel for predictive 3D in vitro drug testing. It serves pharmaceutical, biotech, dermocosmetics, nutraceutical, and academic customers via direct sales, custom assay services, and marketplace partners.

What React4life does

React4Life Srl is a privately held Italian biotech company founded in 2017 by Dr. Silvia Scaglione, headquartered in Genoa. It develops and commercializes the MIVO® (Millifluidic Vessel Organ) organ-on-chip platform, a patented technology that combines clinically relevant 3D tissue size with independently controlled millifluidic flow environments for in vitro drug discovery, toxicity testing, and translational research. The platform includes MIVO® Single Flow and Double Flow chamber kits, the 3D-flowGel ready-to-use hydrogel, and the TOKYO high-throughput fluidic module with 24 parallel lines, supporting applications in cancer and immunology, gut/nutraceuticals, dermocosmetics and medical devices, and biotech/pharmaceutical development. A multi-organ Cancer-Liver-on-Chip configuration and integrated custom assay services extend the platform toward combination efficacy and hepatoxicity studies.

React4Life monetizes through a mix of hardware sales (MIVO® chamber kits, 3D-flowGel, TOKYO module), custom cell-based assay services, and research-use licensing, with pricing handled via quote requests rather than public list prices. The go-to-market combines direct enterprise field sales with marketplace distribution through Scientist.com and Skinobs, supplemented by a heavy content and event presence — webinars, workshops, publications, and industry conference participation — targeting pharma, biotech, dermocosmetics, nutraceutical, and academic customers. Reported performance metrics include 92–95% concordance with clinical drug responses using patient-derived samples and reproducible results with sub-2% standard deviations in dermal absorption assays.

The company is founder-led, with Dr. Scaglione as Chief Scientist and Maurizio Aiello as CEO, holds 7 patents tied to the founder and the company, and has earned recognition including the 2023 CPHI Award, the EU Innovation Radar Award for Best Health Technology, the 2021 Gamma Donna Innovative Start-up Award, and a 2024 European Innovation Council Ambassador nomination. In February 2026 it became a founding member of IAMPS, the European industry association for microphysiological systems providers. Revenue and headcount figures are not publicly disclosed; team size is reported at 1–10 employees.

React4life firmographics

Firmographics
Name
React4life
Legal name
React4Life
Website
https://react4life.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
React4Life Srl is a Genoa-based biotech company developing the MIVO® millifluidic organ-on-chip platform and 3D-flowGel hydrogel for predictive 3D in vitro drug testing. It serves pharmaceutical, biotech, dermocosmetics, nutraceutical, and academic customers via direct sales, custom assay services, and marketplace partners.
Ownership category
akta.pro rank

React4life industry classification

Industry
Product category
Organ-on-Chip Technology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Equipment and Supplies Manufacturing (3391)
SIC
Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Organ-on-chip technology
  • In vitro tissue models
  • Drug discovery platforms
  • 3D cell culture
  • Preclinical testing services

Where React4life is headquartered

Location

Headquarters

HQ city
Genova
HQ country
Italy
HQ region
Europe

Offices1 record

Markets served

React4life business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. MIVO® Hardware Sales: Sale of MIVO® organ-on-chip devices including Single Flow Box (12 MIVO® chambers, 12 single flow lids) and Double Flow Box (12 MIVO® chambers, 12 double flow lids). Devices are sterile and individually blistered for quick and easy use.
  2. Cell-based Assay Services: Expert R&D team collaborates with customers to design and develop tailored assays. Testing services provide more predictive results with high accuracy and reliability, delivering fast and precise data.
  3. 3D-flowGel Sales: Sale of 3D-flowGel 3D cell culture matrix product for in vitro cell culture applications.
  4. Technology Licensing: The company offers technology licensing through terms and conditions for 'Supply of Products and Services – Research Use', indicating licensing arrangements for their proprietary technology.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom quote-based pricing for MIVO® products and services

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

React4life product offering

Product offering

Core offering

React4life develops and manufactures the patented MIVO® (Millifluidic Vessel Organ) organ-on-chip platform, a hardware system that combines clinically relevant 3D tissue models with independently controlled millifluidic flow environments for drug discovery and translational research. The company sells MIVO Single Flow and Double Flow device boxes, the 3D-flowGel hydrogel consumable, and the high-throughput TOKYO fluidic module, and complements these with custom cell-based assay development services for biotech, pharmaceutical, dermocosmetics, and nutraceutical clients.

Product overview

React4Life offers a platform-based product ecosystem centered on the MIVO® millifluidic organ-on-chip technology. The core MIVO® platform is available in Single Flow and Double Flow configurations, combined with 3D-flowGel hydrogel for 3D cell culture. The platform serves four application divisions: Cancer & Immunology (Cancer-on-Chip), Nutraceuticals Food & Feed (Gut-on-Chip), Dermocosmetics Medical Device (Skin-on-Chip), and Biotech Pharmaceutical. Supporting services include custom assay development and scientific support, with resources including publications, workshops, webinars, and application notes documenting research applications.

Differentiator

Problem solved

Functional benefit

Brands

  • MIVO®: Proprietary organ-on-chip technology platform combining clinically relevant tissue size with independent millifluidic environments for drug discovery and toxicity testing.
  • 3D-flowGel
  • TOKYO

Products and services

  • MIVO Single Flow

Quantifiable outcome

  • 92-95% concordance with clinical drug responses vs. conventional 2D cultures
  • +4 more outcomes

Companies that use React4life

Customer profile

Named customers2 records

Segments5 records

Ideal customer profiles4 records

React4life technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

React4life partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • Industry Alliance for Microphysiological Systems (IAMPS)coreStrategic or Co-development Partner · 10 February 2026React4Life is a founding member of IAMPS, the world's first industry association dedicated to representing microphysiological systems providers across Europe. The association aims to increase regulatory acceptance of MPS data, create data-sharing platforms, and advance device standardization. Expected to become operational in Q2 2026.
  • AlveolixcoreStrategic or Co-development PartnerFellow founding member of IAMPS industry alliance, headquartered in Switzerland. Collaborates with React4Life on regulatory acceptance and standardization of MPS technologies.
  • BiomimXcoreStrategic or Co-development PartnerFellow founding member of IAMPS industry alliance from Italy. Part of the nine founding members working to advance microphysiological systems in Europe.
  • ChironcoreStrategic or Co-development PartnerFellow founding member of IAMPS industry alliance from Italy. Contributing to regulatory acceptance and standardization efforts.
  • Dynamic42coreStrategic or Co-development PartnerFellow founding member of IAMPS industry alliance from Germany. Part of the nine founding companies advancing MPS technologies.
  • InSpherocoreStrategic or Co-development PartnerFellow founding member of IAMPS industry alliance from Switzerland. Contributing to data-sharing platforms and device standardization.
  • MIMETAScoreStrategic or Co-development PartnerFellow founding member of IAMPS industry alliance from the Netherlands. Partnered with React4Life on regulatory acceptance and MPS data standards.
  • NETRIcoreStrategic or Co-development PartnerFellow founding member of IAMPS industry alliance from France. Part of the nine founding members advancing organ-on-chip technologies.
  • TissUsecoreStrategic or Co-development PartnerFellow founding member of IAMPS industry alliance from Germany. Partnered with React4Life in this industry association for microphysiological systems.
  • PromoCellminorStrategic or Co-development PartnerJoint webinar collaboration with PromoCell on advancing reproducible 3D cancer models into dynamic cancer-on-chip systems. PromoCell provides cancer media toolbox supporting CSC-driven growth across multiple cancer types.
  • Prodeco PharmaminorStrategic or Co-development PartnerStrategic collaboration between React4Life and Prodeco Pharma to evaluate protective and reparative effects of GSE Reflusolve Rapid using MIVO® esophagus-on-chip platform in GERD research.

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

React4life competitors and assessment

Company assessment

Direct peers

  • Alveolix: Swiss lung-on-chip company with alveolar and airway models for respiratory drug testing. Direct peer in MPS and IAMPS co-founding member serving pharma and inhaled therapeutics customers.
  • MIMETAS: Dutch organ-on-chip company developing the OrganoPlate platform for high-throughput 3D tissue models. Direct peer offering competing organ-on-chip products to pharma R&D, and co-founding member of IAMPS with React4Life.
  • InSphero: Swiss 3D cell culture and organ-on-chip company serving pharma toxicology and disease modeling. Direct peer in microphysiological systems and fellow IAMPS founding member, targeting the same biotech and pharma customers.
  • TissUse: German multi-organ-on-chip company with a HUMIMIC platform for connected organ models. Direct peer in MPS/multi-organ-chip, and fellow IAMPS founding member addressing the same pharma and cosmetics testing customers.
  • Emulate: US-based organ-on-chip company and one of the most capitalized players in the space, with the Emulate platform serving pharma R&D. Direct peer with deeper commercial scale and broader enterprise penetration.
  • CN Bio: UK organ-on-chip company offering the PhysioMimix platform for drug discovery and toxicology. Direct peer targeting the same pharma ADME/Tox and disease modeling applications as React4Life.
  • Dynamic42: German organ-on-chip company developing immune and infection models using microfluidic chip technology. Direct peer and IAMPS founding member addressing pharma and academic customers.
  • NETRI: French organ-on-chip company specializing in neuro-on-chip and microfluidic devices for pharma and cosmetics. Direct peer and IAMPS founding member targeting adjacent applications to React4Life's platform.
  • BiomimX: Italian organ-on-chip company developing multi-organ and disease models. Direct peer in MPS, fellow Italian company, and IAMPS founding member competing for similar European pharma and academic customers.
  • SynVivo (Nortis): US organ-on-chip company providing microfluidic tissue models for drug development and toxicity testing. Direct peer offering competing OoC hardware and services to pharma researchers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

React4life social profiles

Digital presence

React4life financial estimates

Financial estimate

Revenue estimate

Valuation estimate

React4life leadership team

Management profile

Number of profiles

Profiles2 records

React4life funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

React4life M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about React4life

What does React4life do?

React4life develops and manufactures the patented MIVO® (Millifluidic Vessel Organ) organ-on-chip platform, a hardware system that combines clinically relevant 3D tissue models with independently controlled millifluidic flow environments for drug discovery and translational research. The company sells MIVO Single Flow and Double Flow device boxes, the 3D-flowGel hydrogel consumable, and the high-throughput TOKYO fluidic module, and complements these with custom cell-based assay development services for biotech, pharmaceutical, dermocosmetics, and nutraceutical clients.

Is React4life a public or private company?

React4life is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was React4life founded?

React4life was founded in 2017. It employs 11 to 50 people.

Where is React4life based?

React4life is headquartered in Genova, Italy, in the Europe region.

How does React4life make money?

Four revenue lines are on record. MIVO® Hardware Sales are the primary driver. The others are cell-based Assay Services, 3D-flowGel Sales and technology Licensing.

Who are React4life's main competitors?

Direct peers on record are Alveolix, MIMETAS, InSphero, TissUse, Emulate, CN Bio, Dynamic42, NETRI, BiomimX and SynVivo (Nortis).

Does React4life have an API?

No public API is recorded for React4life.

What industry is React4life in?

React4life's product category is Organ-on-Chip Technology. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireIndustry Leaders Announce World’s First Microphysiological Systems Industry Association (IAMPS)European MPS industry leaders announced the creation of the Industry Alliance for Microphysiological Systems (IAMPS), the world's first industry association dedicated to representing microphysiological systems providers across Europe. The founding members include nine companies: Alveolix, BiomimX, Chiron, Dynamic42, InSphero, MIMETAS, NETRI, React4Life, and TissUse, headquartered in Switzerland, Italy, the Netherlands, Germany, and France. IAMPS will work to increase regulatory acceptance of MPS data, create data-sharing platforms, and advance device standardization, with the association expected to become operational in Q2 2026.React4LifeReact4life and Prodeco Pharma Announce Exciting Partnership in Evidence-Based Botanical ResearchReact4life and Prodeco Pharma have announced a strategic partnership to accelerate evidence-based botanical research using React4life's organ-on-chip technology. This collaboration aims to validate the efficacy and safety of phytotherapeutic formulations, reducing development timelines from years to months while minimizing animal testing. The alliance combines React4life's proprietary MIVO® platform with Prodeco Pharma’s expertise in natural medicine to support data-driven product innovation.Wired ItaliaWired Health racconta come il digitale sta trasformando il mondo della saluteWired Health 2022 returns to Base Milano on March 15 for its fifth year, focusing on digital transformation in healthcare. The event covers five themes including robotics, AI, genetics, digital therapies, and tech transfer, with speakers from companies like Philips and Humanitas. It is free to attend and streamed online.LabWorldL’organo su chip per riprodurre in laboratorio la biologia umanaReact4life and Biosigma announced a partnership to distribute the MIVO organ-on-chip in Italy. The chip, which replicates human biology in the lab, was awarded the European Commission's Best Innovation Health 2021. The collaboration aims to make the technology accessible to labs and researchers.EU LoginNews: EIC Pathfinder company React4Life wins IR Prize "Health Tech Innovation" categoryReact4Life, an EIC-funded Italian biotech, won the IR Prize in the 'Innovative Health Tech' category on 21 October. The company's organ-on-a-chip solution supports personalized drug development and accelerates new therapies. It also holds two EU-funded projects, B2B and MOOD.ANSA.itPremio Innovation Radar ad azienda genoveseReact4Life, a Genoa-based company, won a European Commission Innovation Radar 2021 prize for its organ-on-a-chip technology, which supports personalized drug development and accelerates new therapies. The prize was awarded in the health technology category, with other winners including MetGen, C2CA Technology, and Kypo.Millionaire«Per fare impresa? Siate umili, curiose e determinate». I consigli delle finaliste del Premio GammaDonna alle aspiranti imprenditriciSix finalists of Italy's GammaDonna award for innovative female entrepreneurs shared advice for aspiring women entrepreneurs. The award ceremony, including the Giuliana Bertin Communication Award and Women Startup Award, will be broadcast on QVC Italia on November 21. The finalists come from diverse sectors, including horticulture and biotech.ANSA.itLiguria al lavoro in Europa per network sulla sicurezzaLiguria will lead a European security network meeting on 11 February in Brussels, with partners including Alpes Cote d'Azur, Bretagna, and others. The initiative, part of the EU's Smart cities partnership, aims to create a common platform and apply for an Interreg call in April.